目的 探究艾托格列净联合西格列汀治疗2型糖尿病(T2DM)的疗效及安全性观察。方法 回顾性分析2022年1月至2024年2月在上海交通大学医学院附属瑞金医院舟山分院就诊的T2DM患者临床资料，将予以口服西格列汀治疗的54例患者纳入对照组，在对照组基础上予以口服艾托格列净治疗的54例患者纳入观察组。比较2组患者治疗3个月后的临床疗效和治疗期间的不良反应发生情况，比较2组患者治疗前和治疗3个月后的控糖效果[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)]、代谢指标[血尿素氮(BUN)、血同型半胱氨酸(Hcy)]。结果 观察组的总有效率(96。3％)高于对照组(85。2％)(x2=3。967，P<0。05)。在治疗期间，2组的不良反应总发生率差异无统计学意义(x2=0。787，P>0。05)。治疗3个月后，2组患者的FPG、2 h PG、HbA1c、BUN、Hcy均较治疗前下降，且观察组[(5。6±1。1)mmol/L、(7。4±1。5)mmol/L、(6。5±1。3)％、(3。7±0。5)μmol/L、(12。9±2。7)μmol/L]低于对照组[(6。4±1。1)mmol/L、(8。4±1。7)mmol/L、(7。3±1。4)％、(4。3±0。8)μmol/L、(15。4±2。9)μmol/L](P<0。05)。结论 艾托格列净联合西格列汀可改善T2DM患者的控糖效果，调节代谢指标，具有较好的安全性。
Efficacy and safety of ertugliflozin combined with sitagliptin in the treatment of T2DM
Objective To investigate the efficacy and safety of ertugliflozin combined with sitagliptin in the treatment of type 2 diabetes mellitus (T2DM). Methods A retrospective analysis was conducted on the clini-cal data of patients with T2DM who visited Zhoushan Branch,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,from January 2022 to February 2024. All patients were divided into a control group and an observation group,with 54 cases in each group. The control group received oral sitagliptin treatment,while the ob-servation group received oral ertugliflozin treatment on the basis of the same treatment as the control group. The clinical efficacy and incidence of adverse reactions during the treatment period were compared between the two groups after 3 months of treatment. The glycemic control effects[fasting blood glucose (FPG),2-hour postprandial blood glucose (2 h PG),and glycated hemoglobin (HbA1c)]and metabolic indicators[blood urea nitrogen (BUN) and blood homocysteine (Hcy)]were also compared between the two groups before and after 3 months of treatment. Results The total effective rate in observation group (96.3％) was higher than that in control group (85.2％) ( x2=3.967,P<0.05). There was no significant difference in the overall incidence rate of adverse reactions between the two groups during treatment ( x2=0.787,P>0.05). After 3 months of treatment,the levels of FPG,2 h PG,HbA 1c,BUN,Hcy in both groups were significantly decreased compared with those before treatment,and the above levels in observation group[(5.6±1.1) mmol/L,(7.4±1.5) mmol/L,(6.5±1.3)％,(3.7±0.5)μmol/L,(12.9±2.7) μmol/L]were lower than control group[(6.4±1.1) mmol/L,(8.4±1.7) mmol/L,(7.3±1.4)％,(4.3±0.8) μmol/L,(15.4±2.9) μmol/L](P<0.05). Conclusion Ertugliflozin combined with sitagliptin can improve glycemic control,regulate metabolic indicators,and exhibit good safety in patients with T2DM.
万方数据
维普
